PAXLOVID 100 MG — DIN 02527804
RITONAVIR : 100 MG NIRMATRELVIR : 150 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PAXLOVID?
PAXLOVID 100 MG contains RITONAVIR : 100 MG NIRMATRELVIR : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02527804, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 16-Mar-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is PAXLOVID used for?
PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Nirmatrelvir And Ritonavir cost around the world?
Nirmatrelvir And Ritonavir is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Bahrain | retail (max) | 1 | 2 |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 1 |
| Czechia | max producer price (ex-factory) | 1 | 1 |
| Greece | producer price (ex-factory) | 1 | 1 |
| Luxembourg | reimbursement | 1 | 1 |
| Norway | max AUP (pharmacy retail) | 1 | 1 |
| Romania | max producer price | 1 | 1 |
| South Africa | single exit price | 1 | 1 |
10 pack listings across 9 brand entries and 9 price bases, refreshed 07 Sep 2026. Ranges span every Nirmatrelvir And Ritonavir pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Nirmatrelvir And Ritonavir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Nirmatrelvir And Ritonavir — 2 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 2 | 1 | PAXLOVID | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 30 tablets divided in 5 daily-dose blister cards (300 mg nirmatrelvir; 100 mg ritonavir) or 20 tablets divided in 5 daily-dose blister cards (150 mg nirmatrelvir; 100 mg ritonavir); 30 tablets divided in 10 blister cards (300 mg nirmatrelvir; 100 mg ritonavir) or 20 tablets divided in 10 blister cards (150 mg nirmatrelvir; 100 mg ritonavir) |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nirmatrelvir And Ritonavir |
|---|---|
| ATC code | J05AE30 |
| AHFS class | 08:18.48 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02527804 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2527804 |
| Brand name | PAXLOVID |
| Generic / active ingredient | RITONAVIR : 100 MG NIRMATRELVIR : 150 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AE30 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AE |
| Current status | CANCELLED POST MARKET |
| Status date | 16-Mar-2026 |
| Original market date | 2022-08-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PAXLOVID | 100 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02524031 |
2 · Same class — other molecules in ATC J05AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Atazanavir | APO-ATAZANAVIR · JAMP ATAZANAVIR · MYLAN-ATAZANAVIR · REYATAZ · +1 more | 16 | 6 | Yes |
| Darunavir | APO-DARUNAVIR · AURO-DARUNAVIR · DARUNAVIR · M-DARUNAVIR · +6 more | 37 | 5 | Yes |
| Ritonavir | AURO-RITONAVIR · NORVIR · NORVIR SEC | 5 | 2 | Yes |
| Nirmatrelvir And Ritonavir | PAXLOVID | 2 | 1 | Yes |
| Amprenavir | AGENERASE | 3 | 0 | Not in Canada |
| Indinavir | CRIXIVAN | 3 | 0 | Not in Canada |
| Nelfinavir | VIRACEPT · VIRACEPT -250MG · VIRACEPT -50MG | 3 | 0 | Not in Canada |
| Saquinavir | FORTOVASE ROCHE · INVIRASE · INVIRASE - CAP 200MG | 3 | 0 | Not in Canada |
| Fosamprenavir | TELZIR | 2 | 0 | Not in Canada |
| Tipranavir | APTIVUS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.